TP53 and endometrial cancer: The ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) was developed to identify similar subgroups using a combination of immunohistochemistry and mutational analysis, replacing MSI-H with the mismatch repair-deficient group (dMMR) and copy-number-high with the p53-abnormal group [5].